Table 4 Multivariable analysis of prognostic factors for overall and event-free survival from study entry.

From: Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios

Variables

Event-free survival (EFS)

Overall survival (OS)

HR (95% CI)

P value

HR (95% CI)

P value

High FLT3/ITD AR

4.8 (1.1, 21.6)

0.041

3.6 (1.1, 12)

0.034

FLT3/ITD mutation

0.9 (0.6, 1.3)

0.519

0.7 (0.5, 1.1)

0.116

CEBPA mutation

0.2 (0.1, 0.5)

0.001

0.2 (0.0, 0.6)

0.008

NPM1 mutation

0.3(0.1, 0.6)

<0.001

0.2 (0.1, 0.7)

0.006

WT1 mutation

1.8 (1.3, 2.6)

0.001

1.4 (0.9, 2.2)

0.090

Age > 10year

1.2 (1.0, 1.5)

0.084

1.5 (1.2, 2.0)

<0.001

WBC > 50 × 109/L

1.5 (1.2, 1.9)

<0.001

1.2 (0.9, 1.6)

0.198

CNSL

1.2 (0.8, 1.8)

0.418

1.2 (0.8, 2.0)

0.353

High-risk karyotype

0.8 (0.6, 1.0)

0.061

0.8 (0.5, 1.2)

0.258

GO

0.9 (0.7, 1.1)

0.205

1.0 (0.7, 1.2)

0.748

Chemotherapy protocol

1.1 (0.8, 1.5)

0.736

1.0 (0.7, 1.4)

0.861

High-risk group

1.4 (0.6, 3.0)

0.441

1.3 (0.4, 4.1)

0.655

BM blas t(%)

1.0 (1.0, 1.0)

0.272

1.0 (1.0, 1.0)

0.784

Peripheral blasts (%)

1.0 (1.0, 1.0)

0.482

1.0 (1.0, 1.0)

0.549

  1. The multivariable Cox proportional hazards model was used to determine the independent effect of prognostic factors on overall and event-free survival in AML patients.
  2. WBC white blood cell counts, CNSL central nervous system leukemia, CEBPA CCAAT/enhancer binding protein alpha, FLT3-ITD fms-related tyrosine kinase 3, NPM1 nucleophosmin 1, WT1 wilms tumor 1, GO Gemtuzumab ozogamicin treatment.
Back to article page